The Company has completd GLP toxicology studies and anticipates filing the IND and initiating a phase 1 study in the first quarter of 2026. The Company’s JAK2V617F inhibitor program is subject to an ...

Atavistik Bio’s JAK2 V617F mutant-selective inhibitors have the potential to address the significant unmet needs of patients with myeloproliferative neoplasms by providing disease-modifying efficacy ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

Ischemic stroke is a major cause of death and disability, caused by a sudden loss of oxygen supply to the brain due to blocked blood vessels. Recanalization treatments such as intravenous thrombolysis ...